Hammel Emily, Webster Thomas F, Gurney Rich, Heiger-Bernays Wendy
Boston University School of Public Health, Department of Environmental Health, Boston, MA 02118, USA.
Simmons University, Department of Chemistry and Physics, Boston, MA 02115, USA.
iScience. 2022 Mar 2;25(4):104020. doi: 10.1016/j.isci.2022.104020. eCollection 2022 Apr 15.
There are 9,000+ per- and polyfluoroalkyl substances (PFAS) in existence, which makes studying and regulating PFAS individually, or even as small mixtures, infeasible. Multiple PFAS definitions based on structure have been proposed, yet these definitions do not consider the implications for the full suite of organofluorine chemicals. For example, organofluorine pharmaceuticals, whose use may be essential and are found in human serum and wastewater, are not uniformly identified across all definitions. Using nine definitions prepared by various stakeholders, we screened the 360 organofluorine pharmaceuticals approved and used globally between 1954 and 2021. Definitions ranged in their inclusion of organofluorine pharmaceuticals (1%-100%). The most inclusive definitions include several top prescribed pharmaceuticals, e.g., Prozac and Lipitor. This analysis provides a framework against which organizations can make decisions about how best to proceed when defining PFAS.
目前存在9000多种全氟和多氟烷基物质（PFAS），这使得单独研究和监管PFAS，甚至作为小混合物进行研究和监管都不可行。已经提出了多种基于结构的PFAS定义，但这些定义没有考虑到对全套有机氟化学品的影响。例如，有机氟药物的使用可能至关重要，并且在人体血清和废水中都有发现，但并非在所有定义中都能统一识别。我们使用了由不同利益相关者制定的九个定义，对1954年至2021年间全球批准和使用的360种有机氟药物进行了筛选。各定义对有机氟药物的纳入范围有所不同（1% - 100%）。最具包容性的定义包括几种最常用的处方药，例如百忧解和立普妥。该分析提供了一个框架，各组织在定义PFAS时可以据此决定如何以最佳方式推进。
